Evidence map›Paper›PMID 40066819›Full record

ArticleCancer discovery2025

RORγ Bridges Cancer-Driven Lipid Dysmetabolism and Myeloid Immunosuppression.

Augusto Bleve, Martina Incerti, Francesca Maria Consonni, Valentina Garlatti, Giulia Ballerini, Chiara Pandolfo, Marta Noemi Monari, Simone Serio, Daniela Pistillo, Marina Sironi and 8 more

Abstract read
In one paragraph

Article in Cancer discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. The Five-Decade Journey of Small Cell Lung Cancer.Cancer communications (London, England) · 2026
    Review
  9. Review
  10. Review
  11. Review
  12. Myeloid metabolism and its role in immunotherapy of cancer.Journal for immunotherapy of cancer · 2025
    Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Augusto Bleve *Department of Pharmaceutical Sciences, University of Piemonte Orientale "A. Avogadro", Novara, Italy.ORCID 0000-0003-1585-4722
Martina Incerti *Department of Pharmaceutical Sciences, University of Piemonte Orientale "A. Avogadro", Novara, Italy.ORCID 0000-0002-4550-0020
Francesca Maria ConsonniDepartment of Pharmaceutical Sciences, University of Piemonte Orientale "A. Avogadro", Novara, Italy.ORCID 0000-0001-5229-0263
Valentina GarlattiDepartment of Pharmaceutical Sciences, University of Piemonte Orientale "A. Avogadro", Novara, Italy.ORCID 0000-0001-8428-7392
Giulia BalleriniDepartment of Pharmaceutical Sciences, University of Piemonte Orientale "A. Avogadro", Novara, Italy.ORCID 0009-0007-9753-5704
Chiara PandolfoDepartment of Pharmaceutical Sciences, University of Piemonte Orientale "A. Avogadro", Novara, Italy.ORCID 0000-0001-9029-2534
Marta Noemi MonariLaboratory of Clinical Analysis, Humanitas Mater Domini, Varese, Italy.ORCID 0000-0003-4071-270X
Simone SerioInstitute of Genetic and Biomedical Research (IRGB) - National Research Council (CNR), Milan, Italy.ORCID 0000-0002-7294-2094
Daniela PistilloBiobank, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy.ORCID 0000-0002-7665-3783
Marina SironiIRCCS Humanitas Research Hospital, Milan, Italy.ORCID 0000-0002-3342-1149
Chiara AlìDepartment of Pharmaceutical Sciences, University of Piemonte Orientale "A. Avogadro", Novara, Italy.ORCID 0009-0002-0355-6533
Marcello ManfrediDepartment of Translational Medicine, University of Piemonte Orientale, Novara, Italy.ORCID 0000-0003-0632-5618
Elettra BarberisDepartment of Translational Medicine, University of Piemonte Orientale, Novara, Italy.ORCID 0000-0002-2296-9766
Giovanna FinocchiaroMedical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.ORCID 0000-0001-6663-1989
Marco Antonio CassatellaDepartment of Medicine, Section of General Pathology, University of Verona, Verona, Italy.ORCID 0000-0001-7824-1806
Cristina PanicoDepartment of Cardiovascular Medicine, IRCCS Humanitas Research Hospital, Milan, Italy.ORCID 0000-0002-9198-3676
Gianluigi CondorelliDepartment of Cardiovascular Medicine, IRCCS Humanitas Research Hospital, Milan, Italy.ORCID 0000-0003-0481-6843
Antonio SicaDepartment of Pharmaceutical Sciences, University of Piemonte Orientale "A. Avogadro", Novara, Italy.ORCID 0000-0002-8342-7442

Funding

Fondazione AIRC per la ricerca sul cancro ETS (AIRC) 22757Fondazione AIRC per la ricerca sul cancro ETS (AIRC) 29348Fondazione Cariplo (Cariplo Foundation) 2017BA9LM5_001
6 · The paper itself

Abstract

Despite well-documented metabolic and hematopoietic alterations during tumor development, the mechanisms underlying this crucial immunometabolic intersection remain elusive. Of particular interest is the connection between lipid metabolism and the retinoic acid-related orphan receptor (RORC1/RORγ), whose transcriptional activity modulates cancer-related emergency myelopoiesis and is boosted by cholesterol metabolites, whereas hypercholesterolemia itself is associated with dysregulated myelopoiesis. In this study, we show that cancer and hypercholesterolemic diet independently or cooperatively activate RORγ-dependent expansion of myeloid-derived suppressor cells (MDSC) and M2-polarized tumor-associated macrophages (TAM), supporting cancer spread. Moreover, we report that tumor-induced expression of IL1β and IL6 promotes hepatic expression of proprotein convertase subtilisin/kexin type 9 in preclinical models and patients. Importantly, lowering cholesterol levels, by genetic or pharmacologic inhibition of proprotein convertase subtilisin/kexin type 9, prevents MDSC expansion, M2 TAM accumulation, and tumor progression in a RORγ-dependent manner, unleashing specific antitumor immunity. Overall, we identify RORγ as a key sensor of lipid disorders, bridging hypercholesterolemia and protumor myelopoiesis. SIGNIFICANCE: Cancer and a hypercholesterolemic diet independently or collaboratively increase blood cholesterol, which in turn triggers RORγ-dependent expansion of suppressive monocytic MDSCs and M2-like TAMs, thus inhibiting specific antitumor immunity and facilitating disease progression.

Indexed as

Lipid MetabolismMyeloid-Derived Suppressor CellsNeoplasmsNuclear Receptor Subfamily 1, Group F, Member 3AnimalsHumansMiceProprotein Convertase 9Nuclear Receptor Subfamily 1, Group F, Member 3Proprotein Convertase 9

Identifiers

PMID40066819
PMCPMC12223513

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.